| H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers M Seiler, A Yoshimi, R Darman, B Chan, G Keaney, M Thomas, ... Nature medicine 24 (4), 497-504, 2018 | 514 | 2018 |
| Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study AR Mato, NN Shah, W Jurczak, CY Cheah, JM Pagel, JA Woyach, ... The Lancet 397 (10277), 892-901, 2021 | 436 | 2021 |
| Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins SCW Lee, H Dvinge, E Kim, H Cho, JB Micol, YR Chung, BH Durham, ... Nature medicine 22 (6), 672-678, 2016 | 391 | 2016 |
| Diagnosis and classification of hematologic malignancies on the basis of genetics J Taylor, W Xiao, O Abdel-Wahab Blood, The Journal of the American Society of Hematology 130 (4), 410-423, 2017 | 296 | 2017 |
| Somatic mutations and cell identity linked by Genotyping of Transcriptomes AS Nam, KT Kim, R Chaligne, F Izzo, C Ang, J Taylor, RM Myers, ... Nature 571 (7765), 355-360, 2019 | 289 | 2019 |
| Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations AM Intlekofer, AH Shih, B Wang, A Nazir, AS Rustenburg, SK Albanese, ... Nature 559 (7712), 125-129, 2018 | 281 | 2018 |
| Synthetic lethal and convergent biological effects of cancer-associated spliceosomal gene mutations SCW Lee, K North, E Kim, E Jang, E Obeng, SX Lu, B Liu, D Inoue, ... Cancer cell 34 (2), 225-241. e8, 2018 | 231 | 2018 |
| Spliceosomal disruption of the non-canonical BAF complex in cancer D Inoue, GL Chew, B Liu, BC Michel, J Pangallo, AR D’Avino, T Hitchman, ... Nature 574 (7778), 432-436, 2019 | 211 | 2019 |
| Mechanisms of Resistance to Noncovalent Bruton’s Tyrosine Kinase Inhibitors E Wang, X Mi, MC Thompson, S Montoya, RQ Notti, J Afaghani, ... New England Journal of Medicine 386 (8), 735-743, 2022 | 180 | 2022 |
| Diagnosis and Treatment of Myelodysplastic Syndromes: A Review MA Sekeres, J Taylor JAMA 328 (9), 872-880, 2022 | 137 | 2022 |
| Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms DP Steensma, M Wermke, VM Klimek, PL Greenberg, P Font, ... Leukemia 35 (12), 3542-3550, 2021 | 136 | 2021 |
| Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations BH Durham, B Getta, S Dietrich, J Taylor, H Won, JM Bogenberger, ... Blood, The Journal of the American Society of Hematology 130 (14), 1644-1648, 2017 | 122 | 2017 |
| Minor intron retention drives clonal hematopoietic disorders and diverse cancer predisposition D Inoue, JT Polaski, J Taylor, P Castel, S Chen, S Kobayashi, SJ Hogg, ... Nature Genetics 53 (5), 707-718, 2021 | 95 | 2021 |
| Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark J Taylor, M Haddadin, VA Upadhyay, E Grussie, N Mehta-Shah, ... Blood, The Journal of the American Society of Hematology 134 (8), 678-687, 2019 | 95 | 2019 |
| Altered nuclear export signal recognition as a driver of oncogenesis J Taylor, M Sendino, AN Gorelick, A Pastore, MT Chang, AV Penson, ... Cancer discovery 9 (10), 1452-1467, 2019 | 90 | 2019 |
| Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML A Yoshimi, ME Balasis, A Vedder, K Feldman, Y Ma, H Zhang, SCW Lee, ... Blood, The Journal of the American Society of Hematology 130 (4), 397-407, 2017 | 87 | 2017 |
| Sex-biased ZRSR2 mutations in myeloid malignancies impair plasmacytoid dendritic cell activation and apoptosis K Togami, SS Chung, V Madan, CAG Booth, CM Kenyon, L Cabal-Hierro, ... Cancer Discovery 12 (2), 522-541, 2022 | 73 | 2022 |
| Advances in Acute Myeloid Leukemia: Recently Approved Therapies and Drugs in Development M Stanchina, D Soong, B Zheng-Lin, JM Watts, J Taylor Cancers 12 (11), 3225, 2020 | 72 | 2020 |
| Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia AC Leeksma, J Taylor, B Wu, JR Gardner, J He, M Nahas, M Gonen, ... Leukemia 33 (2), 390-402, 2019 | 67 | 2019 |
| Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies J Taylor, D Pavlick, A Yoshimi, C Marcelus, SS Chung, JF Hechtman, ... The Journal of clinical investigation 128 (9), 3819-3825, 2018 | 65 | 2018 |
